Form 13-F position report

* UNITED THERAPEUTICS CORP DE

Reported by Mork Capital Management LLC

UTHR CUSIP 91307C102 Manager CIK 0001626494

Reported 4,100 shares, unchanged from the prior quarter.

Reported value 0.0%; share count 0.0% vs. the prior quarter.

Unchanged
% of reported 13F value 1.38% This manager · Q3 2026
Shares 4,100 Quarter-end amount reported
Reported value $2,221,749 Fair value at quarter end
Consecutive quarters held 48 Through Q3 2026

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2021-12-31 886000
2022-03-31 736000
2022-06-30 966000
2022-09-30 858000
2022-12-31 1140169
2023-03-31 918236
2023-06-30 905075
2023-09-30 926067
2023-12-31 901549
2024-03-31 941852
2024-06-30 1306055
2024-09-30 1469235
2024-12-31 1446644
2025-03-31 1263907
2025-06-30 1178135
2025-09-30 1718761
2025-12-31 1997725
2026-03-31 2431218
2026-06-30 2221503
2026-09-30 2221749

Quarterly position history

How this manager's reported quarter-end position changed over time.

20 quarters
Quarterly reported position history for * UNITED THERAPEUTICS CORP DE held by Mork Capital Management LLC.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q3 2026 Unchanged 4,100 0 (0.0%) 1.38% $2,221,749 2026-11-16
Q2 2026 Unchanged 4,100 0 (0.0%) 1.42% $2,221,503 2026-08-14
Q1 2026 Unchanged 4,100 0 (0.0%) 1.73% $2,431,218 2026-05-15
Q4 2025 Unchanged 4,100 0 (0.0%) 1.22% $1,997,725 2026-02-17
Q3 2025 Unchanged 4,100 0 (0.0%) 1.18% $1,718,761 2025-11-14
Q2 2025 Unchanged 4,100 0 (0.0%) 0.86% $1,178,135 2025-08-14
Q1 2025 Unchanged 4,100 0 (0.0%) 0.99% $1,263,907 2025-05-15
Q4 2024 Unchanged 4,100 0 (0.0%) 0.95% $1,446,644 2025-02-14
Q3 2024 Unchanged 4,100 0 (0.0%) 1.05% $1,469,235 2024-11-14
Q2 2024 Unchanged 4,100 0 (0.0%) 1.02% $1,306,055 2024-08-14
Q1 2024 Unchanged 4,100 0 (0.0%) 0.71% $941,852 2024-05-14
Q4 2023 Unchanged 4,100 0 (0.0%) 0.55% $901,549 2024-02-14
Q3 2023 Unchanged 4,100 0 (0.0%) 0.72% $926,067 2023-11-13
Q2 2023 Unchanged 4,100 0 (0.0%) 0.69% $905,075 2023-08-11
Q1 2023 Unchanged 4,100 0 (0.0%) 0.75% $918,236 2023-05-12
Q4 2022 Unchanged 4,100 0 (0.0%) 0.87% $1,140,169 2023-02-14
Q3 2022 Unchanged 4,100 0 (0.0%) 0.84% $858,000 2022-11-14
Q2 2022 Unchanged 4,100 0 (0.0%) 0.88% $966,000 2022-08-15
Q1 2022 Unchanged 4,100 0 (0.0%) 0.66% $736,000 2022-05-13
Q4 2021 Unchanged 4,100 0 (0.0%) 0.6% $886,000 2022-02-15
Five years are shown. A free account unlocks the complete reported history. Unlock full history

Who else reported the position

962 managers reported * UNITED THERAPEUTICS CORP DE for Q3 2026.

Managers reporting * UNITED THERAPEUTICS CORP DE in Q3 2026.
Manager Activity Shares Change % of reported 13F Reported value Tenure
BlackRock Inc Added 5,575,162 +280,633 0.04% $3,021,124,690 9 qtrs
Avoro Capital Advisors LLC Reduced 2,755,555 -22,222 15.41% $1,493,207,699 24 qtrs
STATE STREET CORPORATION Added 1,952,557 +54,493 0.03% $1,058,071,113 54 qtrs
VANGUARD CAPITAL MANAGEMENT LLC Added 1,928,928 +10,672 0.02% $1,045,266,794 3 qtrs
VANGUARD PORTFOLIO MANAGEMENT LLC Reduced 1,911,530 -7,899 0.05% $1,035,838,992 3 qtrs
WELLINGTON MANAGEMENT GROUP LLP Added 1,899,605 +520,580 0.18% $1,029,376,955 24 qtrs
RENAISSANCE TECHNOLOGIES LLC Reduced 1,675,899 -32,840 1.24% $908,152,909 54 qtrs
AMUNDI Added 988,820 +769,726 0.11% $535,831,670 22 qtrs
GEODE CAPITAL MANAGEMENT LLC Reduced 974,993 -21,605 0.03% $527,238,922 54 qtrs
CITADEL ADVISORS LLC Added 928,464 +623,772 0.06% $503,125,357 8 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
September 30, 2026
Filed
November 16, 2026
Filing type
13F-HR
Position type
COM

Voting authority reported

Sole
4,100
Shared
0
None
0

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.